The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.

Article Details

Citation

Copy to clipboard

Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F

The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.

J Psychiatry Neurosci. 2004 Jul;29(4):252-65.

PubMed ID

15309042 [ View in PubMed

]

Abstract

The selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed antidepressant drugs, because they are well tolerated and have no severe side effects. They rapidly block serotonin (5-HT) reuptake, yet the onset of their therapeutic action requires weeks of treatment. This delay is the result of presynaptic and postsynaptic adaptive mechanisms secondary to reuptake inhibition. The prevention of a negative feedback mechanism operating at the 5-HT autoreceptor level enhances the neurochemical and clinical effects of SSRIs. The blockade of 5-HT2A receptors also seems to improve the clinical effects of SSRIs. These receptors are located postsynaptically to 5-HT axons, mainly in the neocortex. Pyramidal neurons in the prefrontal cortex are particularly enriched in 5-HT2A receptors. Their blockade may affect the function of prefrontal-subcortical circuits, an effect that probably underlies the beneficial effects of the addition of atypical antipsychotic drugs, which are 5-HT2A receptor antagonists, to SSRIs in treatment-resistant patients.

DrugBank Data that Cites this Article

Drugs

Flupentixol

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Mirtazapine	5-hydroxytryptamine receptor 2A	Protein	Humans	Yes	Antagonist	Details